{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-251807","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2022-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.890933+00:00","generated_at":"2026-06-23T07:17:24.064335+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Equillium reports interim itolizumab data in LN: 50% CR at week 28, 67% >80% UPCR reduction","bullets":["Baseline mean UPCR 5.8 g/g; 13 subjects enrolled, 11 reached week 12, 6 reached week 28/EOS.","At week 28: 3/6 (50%) achieved complete response (UPCR <0.7 g/g); 2/6 (33%) partial response.","4/6 (67%) achieved >80% reduction in UPCR; average 60% reduction across all dosed subjects.","No drug-related serious adverse events or treatment discontinuations; steroid tapered to <7.5 mg/day.","Top-line Type B data expected mid-2023; pending Metacrine acquisition also noted in filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-251807","json":"https://secwatch.observer/filing/0001193125-22-251807.json","markdown":"https://secwatch.observer/filing/0001193125-22-251807.md","text":"https://secwatch.observer/filing/0001193125-22-251807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312522251807/0001193125-22-251807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312522251807/d383524d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:17:24.064335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}